National Heart, Lung, and Blood Institute (NHLBI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Heart, Lung, and Blood Institute (NHLBI) sits in the top decile of US sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count).
National Heart, Lung, and Blood Institute (NHLBI): 501 sponsored US clinical trials, 62 recruiting.
National Heart, Lung, and Blood Institute (NHLBI) sponsors 501 registered US clinical trials on ClinicalTrials.gov, 62 of them currently recruiting, and 381 completed. 33 of these trials are in Phase 3-4 (later-stage) and 205 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atherosclerosis, with 12 trials.
Top-decile sponsor footprint
National Heart, Lung, and Blood Institute (NHLBI) ranks in the top decile of sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
381 of 417 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
501 total, page 6 of 11
Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)
NCT00421174
Drug Study of Albuterol to Treat Acute Lung Injury
NCT00434993
Establishing a Repository of Blood and DNA Samples From People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Genotype-Phenotype Database and Sample Repository)
NCT00528203
Niacin to Improve Blood Flow in People With Sickle Cell Disease
NCT00508989
Genes Causing Ebstein's Anomaly
NCT00497705
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease
NCT00495638
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
NCT00488592
Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease
NCT00492531
Imaging of Totally Blocked Arteries
NCT00459446
Stem Cell Transplantation for Patients With Cancers of the Blood
NCT00467961
Effectiveness of an Anger and Stress Management Program on Reducing Blood Pressure Levels in Youth
NCT00508612
Model System for Transient Forearm Blood Vessel Dysfunction
NCT00453531
Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk
NCT00613158
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
NCT00433745
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
NCT00406445
Collection of Heart Tissue Sample During Open Heart Surgery
NCT00423553
Validation of MRI Measurement of Cardiac Blood Flow
NCT00417625
Rilonacept to Improve Artery Function in Patients With Atherosclerosis
NCT00417417
Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease
NCT00391170
Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
NCT00368446
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
NCT00345345
Catheter-Based Treatment of Cardiovascular Disease
NCT00380016
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
NCT00366509
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
NCT00378534
Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
NCT00366418
Predicting Response to Cardiac Resynchronization Therapy in Heart Failure
NCT00359372
Cardiovascular Magnetic Resonance Imaging of Pediatric Normal Volunteers
NCT00353899
Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
NCT00352430
Genetic and Nutritional Causes of Heart Birth Defects
NCT00368732
The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease
NCT00451919
Lifetime Risk for Cardiovascular Disease Among Non-White Ethnic Groups
NCT00377702
An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers
NCT00322127
Telomere Repair Gene Mutation in Inflammatory Bowel Disease
NCT00353639
Sildenafil to Treat HIV-Associated Pulmonary Hypertension
NCT00327080
Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants
NCT00308633
Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)
NCT00471809
Atorvastatin to Treat Pulmonary Sarcoidosis
NCT00279708
Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
NCT00270452
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
NCT00270478
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)
NCT00329030
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
NCT00260689
The Role of Nitrite in Preconditioning Mediated Tolerance to Ischemic Stress
NCT00250185
Effect of Regular Exercise on Vascular Function and Cardiovascular Risk in a Sedentary Work Force
NCT00246883
Alemtuzumab to Treat Severe Aplastic Anemia
NCT00195624
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
NCT00224874
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
NCT00229619
Genomics of In-Stent Restenosis
NCT00341562
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
NCT00130000
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
NCT00217594
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
NCT00201240
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 118 |
| Phase 3 | 29 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Heart, Lung, and Blood Institute (NHLBI) pipeline
62 recruiting of 501 indexed (12% open); 381 completed (76%).
Phase mix: 33 late (III/IV) vs 205 early (I/II) (early-phase heavy).
Top condition: Atherosclerosis (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Heart, Lung, and Blood Institute (NHLBI): open-pipeline peers nationwide
Peers matched on 501 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Heart, Lung, and Blood Institute (NHLBI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 501 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- AstraZeneca · 12% recruiting · 1,285 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- University of Iowa · 12% recruiting · 228 trials
Related
What to do with this National Heart, Lung, and Blood Institute (NHLBI) page
501 registered trials is a research-attention snapshot, not an endorsement of National Heart, Lung, and Blood Institute (NHLBI) or any single study.
- 62 of National Heart, Lung, and Blood Institute (NHLBI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atherosclerosis is the condition National Heart, Lung, and Blood Institute (NHLBI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atherosclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Heart, Lung, and Blood Institute (NHLBI) pipeline card: 501 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.